Deutsche Bank analyst Richard Parkes started Hutchison China MediTech with a Buy rating and $35 price target. The analyst believes the shares offer “significant upside potential” as the company leverages its pipeline of cancer-focused drugs in both domestic and global markets.
https://thefly.com/landingPageNews.php?id=2873559
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.